Compare Jabil Inc (JBL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Novo Nordisk A/S — how do they compare? Jabil Inc trades at $364.78 (market cap $37.37B), while Novo Nordisk A/S trades at $46.03 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.6× Jabil Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| JBL | NVO | |
|---|---|---|
Market Cap | $37.37B | $207.85B |
Sector | Technology | Health |
52-Week High | $385.50 | $63.98 |
52-Week Low | $192.49 | $35.29 |
Enterprise Value | $39.90B | $222.55B |
Dividend Yield | 0.09% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Jabil (JBL) trades at $366.10, up 8.75% in 24 hours, reflecting strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with a consensus price target of $448.29, indicating 22% upside. Recent earnings beats and projected AI revenue growth to over $20 billion by fiscal 2027 (UBS, August 11, 2026) support optimism, though high P/E of 44.63 and thin net margins near 2.6% warrant caution.
Outlook is positive with AI-driven expansion, but risks include valuation sensitivity and competitive pressures. Investment appeal hinges on execution of growth forecasts, while volatility may arise from macroeconomic shifts or supply chain disruptions.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
